問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2025-10-18

王暉景
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

1Cases

2025-06-15 - 2027-04-17

Phase III

Active
A phase 3, external and synthetic placebo-controlled randomized trial, with dose escalation in non-responders, investigated the safety and efficacy of RITLECITINIB 50 mg and 100 mg once daily in adults and adolescents aged 12 years and older with alopecia areata.
  • Condition/Disease

    Suitable for treating patients aged 12 years and older with severe alopecia areata.

  • Test Drug

    Ritlecitinib

Participate Sites
5Sites

Recruiting5Sites